Log In
Print this Print this

Cosentyx, secukinumab (formerly AIN457)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionHuman IgG1 mAb targeting IL-17A
Molecular Target Interleukin-17A (IL-17A)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today